Hogan Lovells advises Valneva in connection with its global offering of approximately 102 million dollars

Valneva is a company specialised in the development and commercialisation of prophylactic vaccines against infectious diseases with significant unmet medical needs. The company has leveraged its expertise and infrastructure to successfully commercialise two vaccines and to rapidly advance a broad range of vaccine candidates in clinical development, including Lyme disease, Chikungunya virus and COVID-19 vaccine candidates.

Following its initial public offering on the NASDAQ in May, Valneva announced, today, the closing on November 2, 2021 of its global offering of 5,175,000 new ordinary shares to specified categories of investors.

Of these millions of ordinary shares, 708,120 are being delivered in the form of 354,060 American Depositary Shares, each representing two ordinary shares, bringing the total gross amount of the Global Offering to approximately 102 million dollars, or 88 million euros.

The Hogan Lovells team consisted of Jean-Marc Franceschi (partner), Madalina Asandului and Claudia Reix (associates).